| Nov 5 |
NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say
|
| Nov 5 |
NeoGenomics: Q3 Earnings Snapshot
|
| Nov 5 |
NeoGenomics Non-GAAP EPS of $0.05 beats by $0.04, revenue of $167.82M beats by $0.79M
|
| Nov 5 |
NeoGenomics Reports Third Quarter 2024 Results
|
| Nov 4 |
NeoGenomics Q3 2024 Earnings Preview
|
| Nov 4 |
Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade
|
| Oct 23 |
NeoGenomics gains conditional approval for solid tumour assays in New York
|
| Oct 22 |
NeoGenomics receives New York state approval for its solid tumor test
|
| Oct 22 |
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
|
| Oct 15 |
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
|
